Clinical trials: gemcitabine hydrochloride
Pancreatic Cancer
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer…
- Trial name
- NCT00026338
- Testing
- erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- 173 sites in United States, Argentina and 17 more
- Volunteers
- 569 people
- Sponsor
- NCIC Clinical Trials Group
Advanced Intrahepatic Cholangiocarcinoma
HYPERION CCA: a Phase 2 Trial of Systemic Therapy With or Without Liver-directed Radiation Therapy for Patients With Advanced Intrahepatic Cholangiocarcinoma
This study will compare outcomes for M1 iCCA patients treated with and without L-RT by reviewing iCCA patients found to have M1 disease at initial diagnosis at a single institution between 2010 and 2021 who received L-RT.
- Trial name
- NCT06858735
- Testing
- Durvalumab, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer
To evaluate the normalization rate of CA 19-9 of individuals with non-metastatic pancreas cancer following up to 6 months of neoadjuvant chemotherapy.
- Conditions
- Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma
- Trial name
- NCT04669197
- Testing
- Paclitaxel protein bound, Gemcitabine, Cisplatin
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- HonorHealth Research Institute
Pancreatic Cancer
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
1.1 Primary Objective To evaluate the effects of short course preoperative erlotinib treatment in a panel of predictive biomarkers from a group of patients who undergo resection of pancreatic adenocarcinoma with curative intent.
- Trial name
- NCT00841035
- Testing
- erlotinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Alabama at Birmingham
Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma
Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer
This phase I trial studies the side effects and best dose of mirvetuximab soravtansine and gemcitabine hydrochloride in treating patients with folate receptor (FR) alpha-positive ovarian, primary peritoneal, fallopian tube…
- Conditions
- Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02996825
- Testing
- Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- City of Hope Medical Center
Malignant Pleural Mesothelioma
Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
Mesothelioma is an aggressive form of cancer. Treatments are available, but for many people, a cure isn't possible. This thesis is to assess the efficacy and safety of switch-maintenance Gemcitabine in Mesothelioma patients after…
- Trial name
- NCT05660616
- Testing
- Gemcitabine, supportive care
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Ain Shams University
Pancreatic Cancer
Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer
The purpose of this study is to investigate whether the addition of panitumumab to radiotherapy plus gemcitabine will increase the number of patients who are alive and progression free at 7 months.
- Trial name
- Vectibix (NCT01175733)
- Testing
- Panitumumab
- Where
- Netherlands
- Volunteers
- 18 people
- Sponsor
- Amsterdam UMC, location VUmc
Cholangiocarcinoma Resectable
Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA
Biliary tract cancer is a highly aggressive and heterogeneous group of gastrointestinal cancers that arise from the intra- or extrahepatic bile ducts (CCA), or the gallbladder (GBC)(1-3).
- Trial name
- NEOLANGIO (NCT06569225)
- Testing
- Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Advanced Cancer
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
This is an Open-Label, Dose-Escalation and Expansion, Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of IMC-002 in Patients with Advanced Cancer Failed to Standard Therapy
- Trial name
- NCT05276310
- Testing
- IMC-002
- Where
- 3 sites in South Korea
- Volunteers
- 86 people
- Sponsor
- ImmuneOncia Therapeutics Inc.
Recurrent Uterine Corpus Sarcoma, Uterine Corpus Leiomyosarcoma
Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00031629
- Testing
- Docetaxel, Filgrastim, Gemcitabine Hydrochloride
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Gynecologic Oncology Group
Specific Advanced Solid Tumors
Escalating Doses of PM01183 in Combination With Gemcitabine in Patients With Specific Unresectable Solid Tumors
Phase I multicenter, open-label, clinical and pharmacokinetic study of PM01183 in combination with gemcitabine in non-heavily pretreated patients with selected advanced solid tumors to determine the maximum tolerated dose (MTD)…
- Trial name
- NCT01970553
- Testing
- lurbinectedin (PM01183), Gemcitabine
- Where
- 3 sites in Spain, United Kingdom
- Volunteers
- 47 people
- Sponsor
- PharmaMar
Hodgkin Disease
A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma
The purpose of this study is to evaluate if the addition of Bortezomib (Velcade) to IGEV combination (Ifosfamide, Gemcitabine and Vinorelbine) in patients with relapsed/refractory Hodgkin's lymphoma increases the rate of complete…
- Trial name
- NCT00636311
- Testing
- Ifosfamide, Gemcitabine, Vinorelbine, Bortezomib + IGEV
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Istituto Clinico Humanitas
Advanced Solid Tumor
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
This is a phase Ib/II, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of JS015 combination therapy in patients with advanced solid tumors.
- Trial name
- NCT06139211
- Testing
- JS015, Toripalimab, Paclitaxel
- Where
- China
- Volunteers
- 66 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
NK-T-Cell Lymphoma, Extranodal
A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.
Extranodal natural-killer (NK)/T-cell lymphoma (ENKTL) is an aggressive subtype of non-Hodgkin lymphoma with a poor prognosis. Notably, patients with advanced-stage disease or early-stage non-upper aero-digestive tract (NUAT)…
- Trial name
- NCT06953739
- Testing
- P-GEMD, P-Gemox
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Ovarian Neoplasms
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
This study specifically aims to evaluate how well mocertatug rezetecan (Mo-Rez) in combination with bevacizumab works in treating platinum-sensitive ovarian cancer compared to standard treatments by checking whether it makes…
- Trial name
- NCT07684612
- Testing
- Mocertatug rezetecan (Mo-Rez), Carboplatin, Paclitaxel
- Where
- 9 sites in Australia, Canada and 2 more
- Volunteers
- 690 people
- Sponsor
- GlaxoSmithKline
Carcinoma, Hepatocellular
Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)
This study is to evaluate the efficacy and safety of Sorafenib in combination with Gemcitabine in patients with advanced/unresectable HCC.
- Trial name
- NCT00703365
- Testing
- Sorafenib and Gemcitabine
- Where
- 3 sites in Thailand
- Volunteers
- 45 people
- Sponsor
- Mahidol University
Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma
Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase II trial studies how well ATR kinase inhibitor M6620 (M6620) and gemcitabine hydrochloride work compared to standard treatment with gemcitabine hydrochloride alone in treating patients with ovarian, primary…
- Conditions
- Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02595892
- Testing
- Berzosertib, Gemcitabine, Gemcitabine Hydrochloride
- Where
- 17 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00885066
- Testing
- capecitabine, erlotinib hydrochloride, gemcitabine hydrochloride
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Antoine Lacassagne
Solid Tumors
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients
The goal of this clinical research study is to find the highest safe dose of the drug Velcade (bortezomib) that can be given together with gemcitabine and pegylated liposomal doxorubicin (Doxil) in the treatment of advanced…
- Trial name
- NCT00500422
- Testing
- Doxil, Gemcitabine, Velcade
- Where
- United States
- Volunteers
- 134 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine…
- Trial name
- NCT05104866
- Testing
- Dato-DXd, Capecitabine, Gemcitabine
- Where
- 167 sites in United States, Argentina and 18 more
- Volunteers
- 732 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.